Total centers (N=987)
Total patients (N=5223)

CRFs collected
Total centers (N=978)
Total patients (N=5181)

CRFs not collected
Total centers (N=9)
Total patients (N=42)

Safety analysis set (N=4219)

Excluded from safety analysis set (N=962)
- Documented glargine administration data outside of observation period (n=2)
- Duplicate (n=4)
- Not registered during study (n=32)
- Not administered (n=6)
- No information after administration (n=20)
- OAD not administered over 12 weeks (n=67)
- Lack of laboratory data during pre-study 4-wk period (HbA1c, weight, height) (n=619)
- Baseline HbA1c < 7.9% or ≥ 12.5% (n=112)
- BMI ≥ 30kg/m2 (n=84)
- Lack of evaluation of overall safety (n=4)
- Using insulin (n=73)
- Not administered OAD (n=30)

Insulin-naïve group (N=3732)

Insulin non-naïve group: Switching from other insulin to insulin glargine (N=487)